MedTrace Logo

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms

NCT03468244 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-02-26

No results posted yet for this study

Summary

A single arm, open-label pilot study is designed to determine the safety, tolerability and effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma

Conditions

  • Advanced Esophageal Squamous Carcinoma
  • Gastric Adenocarcinoma
  • Pancreatic Adenocarcinoma
  • Colorectal Adenocarcinoma

Interventions

BIOLOGICAL

Personalized mRNA Tumor Vaccine

subcutaneous injection with personalized mRNA tumor vaccine at least four times

Sponsors & Collaborators

  • Stemirna Therapeutics

    collaborator INDUSTRY

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Xianbao Zhan, Dr. · Chanhai hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03468244 on ClinicalTrials.gov